RBNZ Capital consultation paper
Australia and New Zealand Banking Group Limited ABN 11 005 357 522
News Release
For release: 14 December 2018
RBNZ Capital consultation paper
RBNZ today released a 58 page consultation paper titled “Capital Review Paper 4”.
Responses are due in March 2019.
ANZ is currently reviewing the consultation paper and will update the market once it has
done so.
For media enquiries contact:
Stephen Ries, +61 409 655 551 (Aus)
Emma Mellow, +64 21 614 165 (NZ)
For analyst enquiries contact:
Jill Campbell, +61 412 047 448 (Aus)
Cameron Davis, +61 421 613 819 (Aus)
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- WBC — Westpac Banking Corporation: Westpac acknowledges capital consultation paper by the RBNZ2018-12-15
“ASX ANNOUNCEMENT 14 December 2018 Westpac acknowledges the release of a consultation paper by the Reserve Bank of New Zealand (RBNZ) - Capital Review Paper 4: How much capital is enough? The RBNZ has today released a new consultation paper to seek the public’s view on…”
- HGH — Heartland Group Holdings Limited: HGH notes RBNZ Capital Review Consultation Paper2018-12-17
“NZX/ASX Release Heartland Group Holdings notes RBNZ Capital Review Consultation Paper 17 December 2018 The Reserve Bank of New Zealand (RBNZ) has released a consultation paper titled “Capital Review Paper 4: How much capital is enough?” The purpose of this paper is…”
- WBC — Westpac Banking Corporation: Westpac 2018 Full Year Financial Results Announcement2018-11-04
“2018 Full Year financial results Significant Developments 78 | Westpac Group 2018 Full Year Financial Results Announcement OTC derivatives reform International regulatory reforms relating to over-the-counter (OTC) derivatives continue to be implemented across the globe…”